sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation
Background: Renal sympathetic denervation (RSD) has provided promising data in its ability to treat therapy resistant arterial hypertension. The effect of RSD on sST-2, a promising biomarker for risk stratification in cardiovascular diseases, has so far not been systematically studied. Methods: We e...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/11/23/11130 |
| _version_ | 1797508138727899136 |
|---|---|
| author | Albert Topf Vera Paar Janine Grueninger Bernhard Wernly Kristen Kopp Thomas Weber Christiana Schernthaner Moritz Mirna Sarah X. Gharibeh Robert Larbig Rudin Pistulli Uta C. Hoppe Michael Lichtenauer Lukas J. Motloch Mathias C. Brandt |
| author_facet | Albert Topf Vera Paar Janine Grueninger Bernhard Wernly Kristen Kopp Thomas Weber Christiana Schernthaner Moritz Mirna Sarah X. Gharibeh Robert Larbig Rudin Pistulli Uta C. Hoppe Michael Lichtenauer Lukas J. Motloch Mathias C. Brandt |
| author_sort | Albert Topf |
| collection | DOAJ |
| description | Background: Renal sympathetic denervation (RSD) has provided promising data in its ability to treat therapy resistant arterial hypertension. The effect of RSD on sST-2, a promising biomarker for risk stratification in cardiovascular diseases, has so far not been systematically studied. Methods: We evaluated serum levels of sST-2 and clinical parameter including left ventricular mass (LVM) in 54 patients with resistant hypertension (RH) undergoing bilateral RSD at baseline as well as at one and/or three months. Results: After RSD, mean office blood pressure showed a significant decrease after one month (<i>p</i> < 0.001). On echocardiography a reduction of LVM was observed at three months (<i>p</i> < 0.01). This was accompanied by a significant decrease of sST-2 levels at three months (sST-2 baseline: 6310.1 ± 3246.0 pg/mL vs. sST-2 three months: 4703.8 ± 1585.9 pg/mL, <i>p</i> = 0.048). Furthermore, baseline sST-2 levels were positively correlated with systolic blood pressure at one month (r = 0.514, <i>p</i> < 0.01) but not three months, indicating a potential predictive value of sST-2 for early intervention success. Conclusion: In patients with RH, RSD is associated with a significant decrease of sST-2 levels after three months, indicating sST-2 to be involved in remodeling processes after RSD. Furthermore, lower sST-2 levels at baseline might be a potential predictor of early intervention success of RSD. |
| first_indexed | 2024-03-10T04:58:03Z |
| format | Article |
| id | doaj.art-4ba7371c762c47f48f43c956248ed8b3 |
| institution | Directory Open Access Journal |
| issn | 2076-3417 |
| language | English |
| last_indexed | 2024-03-10T04:58:03Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Applied Sciences |
| spelling | doaj.art-4ba7371c762c47f48f43c956248ed8b32023-11-23T02:03:09ZengMDPI AGApplied Sciences2076-34172021-11-0111231113010.3390/app112311130sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic DenervationAlbert Topf0Vera Paar1Janine Grueninger2Bernhard Wernly3Kristen Kopp4Thomas Weber5Christiana Schernthaner6Moritz Mirna7Sarah X. Gharibeh8Robert Larbig9Rudin Pistulli10Uta C. Hoppe11Michael Lichtenauer12Lukas J. Motloch13Mathias C. Brandt14Department of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaKardiologische Abteilung, Klinikum Wels-Grieskirchen, Grieskirchnerstrasse 42, 4600 Wels, AustriaDepartment of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDivision of Cardiology, Hospital Maria Hilf Moenchengladbach, 41063 Moenchengladbach, GermanyDepartment of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Albert Schweitzer Campus 1, A1, 48149 Münster, GermanyDepartment of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaBackground: Renal sympathetic denervation (RSD) has provided promising data in its ability to treat therapy resistant arterial hypertension. The effect of RSD on sST-2, a promising biomarker for risk stratification in cardiovascular diseases, has so far not been systematically studied. Methods: We evaluated serum levels of sST-2 and clinical parameter including left ventricular mass (LVM) in 54 patients with resistant hypertension (RH) undergoing bilateral RSD at baseline as well as at one and/or three months. Results: After RSD, mean office blood pressure showed a significant decrease after one month (<i>p</i> < 0.001). On echocardiography a reduction of LVM was observed at three months (<i>p</i> < 0.01). This was accompanied by a significant decrease of sST-2 levels at three months (sST-2 baseline: 6310.1 ± 3246.0 pg/mL vs. sST-2 three months: 4703.8 ± 1585.9 pg/mL, <i>p</i> = 0.048). Furthermore, baseline sST-2 levels were positively correlated with systolic blood pressure at one month (r = 0.514, <i>p</i> < 0.01) but not three months, indicating a potential predictive value of sST-2 for early intervention success. Conclusion: In patients with RH, RSD is associated with a significant decrease of sST-2 levels after three months, indicating sST-2 to be involved in remodeling processes after RSD. Furthermore, lower sST-2 levels at baseline might be a potential predictor of early intervention success of RSD.https://www.mdpi.com/2076-3417/11/23/11130resistant arterial hypertensionrenal denervationsST2 |
| spellingShingle | Albert Topf Vera Paar Janine Grueninger Bernhard Wernly Kristen Kopp Thomas Weber Christiana Schernthaner Moritz Mirna Sarah X. Gharibeh Robert Larbig Rudin Pistulli Uta C. Hoppe Michael Lichtenauer Lukas J. Motloch Mathias C. Brandt sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation Applied Sciences resistant arterial hypertension renal denervation sST2 |
| title | sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation |
| title_full | sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation |
| title_fullStr | sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation |
| title_full_unstemmed | sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation |
| title_short | sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation |
| title_sort | sst2 predicts short term therapy success in patients with therapy resistant hypertension after renal sympathetic denervation |
| topic | resistant arterial hypertension renal denervation sST2 |
| url | https://www.mdpi.com/2076-3417/11/23/11130 |
| work_keys_str_mv | AT alberttopf sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT verapaar sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT janinegrueninger sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT bernhardwernly sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT kristenkopp sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT thomasweber sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT christianaschernthaner sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT moritzmirna sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT sarahxgharibeh sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT robertlarbig sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT rudinpistulli sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT utachoppe sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT michaellichtenauer sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT lukasjmotloch sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation AT mathiascbrandt sst2predictsshorttermtherapysuccessinpatientswiththerapyresistanthypertensionafterrenalsympatheticdenervation |